These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 25781031)

  • 1. Impact of ten-valent pneumococcal conjugate vaccination on invasive pneumococcal disease in Finnish children--a population-based study.
    Jokinen J; Rinta-Kokko H; Siira L; Palmu AA; Virtanen MJ; Nohynek H; Virolainen-Julkunen A; Toropainen M; Nuorti JP
    PLoS One; 2015; 10(3):e0120290. PubMed ID: 25781031
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term impact of 10-valent pneumococcal conjugate vaccination on invasive pneumococcal disease among children in Finland.
    Rinta-Kokko H; Palmu AA; Auranen K; Nuorti JP; Toropainen M; Siira L; Virtanen MJ; Nohynek H; Jokinen J
    Vaccine; 2018 Apr; 36(15):1934-1940. PubMed ID: 29526371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pneumococcal Conjugate Vaccine and Clinically Suspected Invasive Pneumococcal Disease.
    Palmu AA; Kilpi TM; Rinta-Kokko H; Nohynek H; Toropainen M; Nuorti JP; Jokinen J
    Pediatrics; 2015 Jul; 136(1):e22-7. PubMed ID: 26077477
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of 10-valent pneumococcal conjugate vaccine estimated with three parallel study designs among vaccine-eligible children in Finland.
    Rinta-Kokko H; Auranen K; Toropainen M; Nuorti JP; Nohynek H; Siira L; Palmu AA
    Vaccine; 2020 Feb; 38(6):1559-1564. PubMed ID: 31791813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recurrent invasive pneumococcal disease in children--host factors and vaccination response.
    Ingels HA
    Dan Med J; 2015 Jul; 62(7):. PubMed ID: 26183055
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of ten-valent pneumococcal conjugate vaccine on pneumonia in Finnish children in a nation-wide population-based study.
    Palmu AA; Rinta-Kokko H; Nohynek H; Nuorti JP; Kilpi TM; Jokinen J
    PLoS One; 2017; 12(3):e0172690. PubMed ID: 28249015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term population impact of infant 10-valent pneumococcal conjugate vaccination on invasive pneumococcal disease in adults in Finland.
    Nuorti JP; Rinta-Kokko H; Toropainen M; Siira L; Nohynek H; Palmu AA
    Vaccine; 2022 Sep; 40(41):5950-5958. PubMed ID: 36075797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Invasive pneumococcal diseases in children and adults before and after introduction of the 10-valent pneumococcal conjugate vaccine into the Austrian national immunization program.
    Richter L; Schmid D; Kanitz EE; Zwazl I; Pöllabauer E; Jasinska J; Burgmann H; Kundi M; Wiedermann U
    PLoS One; 2019; 14(1):e0210081. PubMed ID: 30629620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact and effectiveness of the 10-valent pneumococcal conjugate vaccine on invasive pneumococcal disease among children under 5 years of age in the Netherlands.
    Peckeu L; van der Ende A; de Melker HE; Sanders EAM; Knol MJ
    Vaccine; 2021 Jan; 39(2):431-437. PubMed ID: 33243632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of a 3 + 0 pneumococcal conjugate vaccine schedule against invasive pneumococcal disease among a birth cohort of 1.4 million children in Australia.
    Gidding HF; McCallum L; Fathima P; Moore HC; Snelling TL; Blyth CC; Jayasinghe S; Giele C; de Klerk N; Andrews RM; McIntyre PB;
    Vaccine; 2018 May; 36(19):2650-2656. PubMed ID: 29627233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway.
    Steens A; Bergsaker MA; Aaberge IS; Rønning K; Vestrheim DF
    Vaccine; 2013 Dec; 31(52):6232-8. PubMed ID: 24176490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of ten-valent pneumococcal conjugate vaccine on invasive pneumococcal disease among children <2 years old: A prospective population-based study in rural Bangladesh.
    Malaker R; Hasanuzzaman M; Hooda Y; Rahman H; Chandra Das R; Kanon N; Saha S; Tanmoy AM; Ranjan Chakraborty S; Saha S; Islam M; Darmstadt GL; Baqui AH; Sathosam M; El-Arifeen S; Whitney CG; Saha SK
    Vaccine; 2024 Jan; 42(2):255-262. PubMed ID: 38071104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of ten-valent pneumococcal conjugate vaccine on invasive pneumococcal disease and nasopharyngeal carriage in Kenya: a longitudinal surveillance study.
    Hammitt LL; Etyang AO; Morpeth SC; Ojal J; Mutuku A; Mturi N; Moisi JC; Adetifa IM; Karani A; Akech DO; Otiende M; Bwanaali T; Wafula J; Mataza C; Mumbo E; Tabu C; Knoll MD; Bauni E; Marsh K; Williams TN; Kamau T; Sharif SK; Levine OS; Scott JAG
    Lancet; 2019 May; 393(10186):2146-2154. PubMed ID: 31000194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distribution of invasive Streptococcus pneumoniae serotypes before and 5 years after the introduction of 10-valent pneumococcal conjugate vaccine in Brazil.
    Brandileone MC; Almeida SCG; Minamisava R; Andrade AL
    Vaccine; 2018 May; 36(19):2559-2566. PubMed ID: 29650385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term surveillance of invasive pneumococcal disease: The impact of 10-valent pneumococcal conjugate vaccine in the metropolitan region of Salvador, Brazil.
    Reis JN; Azevedo J; de Oliveira AML; Menezes APO; Pedrosa M; Dos Santos MS; Ribeiro LC; Freitas HF; Gouveia EL; Teles MB; Carvalho MDG; Reis MG; Nascimento-Carvalho C; Verani JR
    Vaccine; 2024 Jan; 42(3):591-597. PubMed ID: 38184393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Twelve years of pneumococcal conjugate vaccination in the Netherlands: Impact on incidence and clinical outcomes of invasive pneumococcal disease.
    Vestjens SMT; Sanders EAM; Vlaminckx BJ; de Melker HE; van der Ende A; Knol MJ
    Vaccine; 2019 Oct; 37(43):6558-6565. PubMed ID: 31500963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Childhood Pneumococcal Conjugate Vaccine on Nonnotified Clinically Suspected Invasive Pneumococcal Disease in Australia.
    Gidding HF; Sheridan S; Fathima P; Moore HC; Liu B; McIntyre PB; Palmu AA;
    Pediatr Infect Dis J; 2019 Aug; 38(8):860-865. PubMed ID: 30985507
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term Impact of a "3 + 0" Schedule for 7- and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease in Australia, 2002-2014.
    Jayasinghe S; Menzies R; Chiu C; Toms C; Blyth CC; Krause V; McIntyre P
    Clin Infect Dis; 2017 Jan; 64(2):175-183. PubMed ID: 27986682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of the pneumococcal conjugate vaccines on invasive pneumococcal disease in France, 2001-2012.
    Lepoutre A; Varon E; Georges S; Dorléans F; Janoir C; Gutmann L; Lévy-Bruhl D; ;
    Vaccine; 2015 Jan; 33(2):359-66. PubMed ID: 25448105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluating the impact of PCV-10 on invasive pneumococcal disease in Brazil: A time-series analysis.
    Andrade AL; Minamisava R; Policena G; Cristo EB; Domingues CM; de Cunto Brandileone MC; Almeida SC; Toscano CM; Bierrenbach AL
    Hum Vaccin Immunother; 2016; 12(2):285-92. PubMed ID: 26905679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.